Fonden har til formål med almennyttigt sigte at eje og drive BioInnovation Institute og at fremme forskning, innovation og iværksætteri til gavn for almenheden, herunder ved at finansiere og støtte udvikling af opfindelser, opdagelser og selskaber inden for bioteknologi- og life science-sektoren, for derved at skabe et grundlag for vækst og jobskabelse inden for bioteknologi og life science. Fonden kan også yde støtte til andre almennyttige videnskabelige formål inden for bioteknologi og life science.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 87.9 mio. | 191.7 mio. | 882.2 mio. | 738.3 mio. | 126 | |
CVR: 41898666
Secondary names: BioInnovation Institute Foundation (Fond), BII-Fonden, BII Foundation (Fond)
James Walter Glasheen joined the board
Hans Thalsgård Schambye left the board
Companies in the same industry and area
CVR 11679935
CVR 33044380
CVR 34671834
CVR 18784106
CVR 21449148
Compared to 112 companies in Trusters aktiviteter
Comparison is based on industry median values
The financial health of BioInnovation Institute Fonden appears robust, marked by significant profitability and a strong equity position. In 2025, the company reported a revenue of 87.9 million DKK and a profit of 191.7 million DKK, reflecting a notable increase in revenue from 64.8 million DKK in 2024, despite a decrease in profit during the same period. The equity has remained substantial, totaling 738.3 million DKK in 2025, indicating a solid foundation for future growth. Overall, the company is on a strong upward trajectory, showcasing impressive margins and a growing presence within the trust activities sector.
AI-generated summary
companydata.dk